Tom Engber

Tom directs Disarm Therapeutic’s translational strategy to advance the company’s pipeline into the clinic. His work in neuroscience spans three decades and includes research and leadership positions at the National Institutes of Health, Cephalon, Pfizer, Biogen and most recently Takeda Pharmaceuticals, where he was responsible for evaluating new technologies and advancing the company’s CNS portfolio through partnerships. Throughout his career, Tom has led teams bringing new therapeutics from discovery through clinical development. He is the author of more than 50 peer-reviewed articles and an inventor on numerous issued and pending patents.